

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this Application:

Listing of Claims:

1. (Currently Amended) A composition for the treatment, prevention or management of a condition in primates, especially humans comprising a phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity.
2. (Currently Amended) The composition of claim 1 wherein the hyperglycemia is due to a diabetic condition~~condition is Type 2 diabetes or non-insulin dependent diabetes mellitus.~~
3. (Canceled)
4. (Canceled)
5. (Original) The composition of claim 1 wherein the phenolic antioxidant is of plant origin.
6. (Original) The composition of claim 1 wherein the chromium content in the complex is 0.01 to 20% of the complex.
7. (Original) The composition of claim 6 wherein the chromium content in the complex is from 0.02 to 10%.
8. (Currently Amended) The composition of claim 1 wherein the chromium is trivalent ~~in nature.~~
9. (Currently Amended) The composition of claim 1 wherein the phenolic antioxidants ~~include~~ comprises low molecular weight hydrolyzable tannins having a molecular weight below 2,000.
10. (Original) The composition of claim 9 wherein the phenolic antioxidant is obtained from the genus Phyllanthus, Terminalia, Gardenia, Geranium, Erodium or Tamarix.

11. (Currently Amended) The composition of claim 9 wherein the hydrolyzable tannins ~~are-is~~ obtained from *Phyllanthus emblica* (syn. *Emblica officinalis*), *Phyllanthus amarus*, *Phyllanthus flexusus*, other *Phyllanthus* species, *Terminalia bellerica*, and other *Terminalia* species, *Erodium pelagonium*, *Geranium thunbergi*, *Tamarix aphylla* or another *Tamarix* species.

12. (Canceled)

13. (Currently Amended) The composition of claim 11 wherein the hydrolyzable tannins ~~are-is~~ obtained from the *Phyllanthus emblica* fruit.

14. (Currently Amended) ~~A—The composition of claim 1 comprising wherein the phenolic antioxidant chromium complex(s) ofcomprises oxygenated dibenzo- α -pyrone (DBP) or its conjugatesa DBP conjugate, including dimers and oligomers and fulvic acids for the treatment, prevention or management of Type 2 diabetes or glucose tolerance in primates, especially humans.~~

15. (Currently Amended) The composition of claim 14 wherein the oxygenated dibenzo- α -pyrone (DBP) or its DBP conjugates, ~~including comprises~~ dimers and oligomers and fulvic acids ~~are obtained from purified Shilajit~~.

16. (Currently Amended 1) ~~A—The composition of claim 1, comprising chromium complex(s) ofwherein the phenolic anti-oxidant fractions ofis obtained from *Phyllanthus emblica* and/or purified Shilajit, for the treatment, prevention or management of Type 2 diabetes or glucose intolerance.~~

17. (Original) The composition of claim 1 wherein the phenolic antioxidant-chromium complex is prepared by reacting a trivalent chromium salt with a phenolic antioxidant(s).

18. (Original) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with a phenolic antioxidant(s) in an aqueous system.

19. (Original) The composition of claim 18 wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with low molecular weight tannins having a molecular weight below 2,000.

20. (Currently Amended) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with ~~oxygenated dibenzo-a-pyrone (DBP) or its conjugates, including dimers and oligomers and fulvic acids of phenolic antioxidant from purified Shilajit in an aqueous system.~~

21. (Original) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is obtained by spray, freeze, tray or vacuum drying.

22. (Original) A formulation of the composition of claim 1 wherein the phenolic antioxidant-chromium complex is combined with a pharmaceutically or nutritionally acceptable excipient.

23. (Cancelled)

24. (Currently Amended) The composition of claim 1 ~~which also includes further comprising an added additional~~ active ingredient.

25. (Currently Amended) The composition of claim 24 wherein ~~said added the additional~~ active ingredient is an antioxidant, vitamin, carnitine, carnosine, N-acetyl-L-cysteine, biotin, polycosanol, aminoguanidine, α -fatty acid or plant extract, or mixtures thereof.

26. (Currently Amended) The composition of claim 7 wherein the chromium content in the complex is from 1 to 8% of the complex.

27. (Original) The composition of claim 19 wherein the molecular weight of said tannins is below 1,000.

28. (Currently Amended) A method of treatment for hyperglycemia—treating, preventing or managing a condition in primates, especially humans which comprises treating administering to a mammal said primate, especially human with the composition of claim 1.

29. (Currently Amended) TheA method of claim 28 wherein the hyperglycemia is the result of a diabetic condition~~said condition is Type 2 diabetes or glucose intolerance.~~

30. (Currently Amended) ~~The~~^A formulation of claim 22 wherein the phenolic antioxidant-chromium complex ~~having~~ has 10 to 1,000 μ g of chromium content is combined with a pharmaceutically or nutritionally acceptable excipient to improve insulin sensitivity, reduce blood glucose, glycated hemoglobin, reduce total cholesterol and low density lipids in primates, especially humans.

31. (Currently Amended) The composition of claim 17 wherein the phenolic antioxidant-chromium complex is prepared by dry blending ~~a trivalent chromium salt or a complex with a phenolic antioxidant(s).~~

32. (Currently Amended) The composition of claim 31 wherein the phenolic antioxidant-chromium complex is prepared by ~~dry blending~~derived from chromium chloride, acetate, or formate, picolinate, nicotinate or polynicotinate ~~with a phenolic antioxidant(s).~~

33. (Currently Amended) The composition of claim 31 wherein the phenolic antioxidant-chromium complex is prepared by ~~dry blending~~ chromium chloride, acetate, formate, nicotinate, polynicotinate or picolinate ~~with phenolic antioxidant is oxygenated dibenzo- α -pyrone (DBP), or DBP conjugate its conjugates, including dimmers and oligomers and or fulvic acids of purified Shilajit.~~

34. (Currently Amended) ~~A~~^{The} ~~composition~~formulation of claim 31 wherein the phenolic antioxidant-chromium blend complex ~~has~~ has 10 to 1,000 μ g of chromium ~~and~~ is combined with a pharmaceutically or nutritionally acceptable excipient to improve Type 2 diabetes, glucose intolerance, insulin sensitivity, reduce blood glucose, glycated hemoglobin, reduce total cholesterol and low density lipid in primates, especially humans.

35. (Currently Amended) ~~A~~^{The} ~~method of claim 28 wherein the composition pharmaceutical or nutritional preparation of claim 34~~ is administered once or twice a day to a primate, especially human.

36. (New) The composition of claim 15, wherein the oxygenated dibenzo- α -pyrone (DBP), DBP conjugate, and fulvic acid are obtained from purified Shilajit.

37. (New) The composition of claim 33, wherein the oxygenated dibenzo- α -pyrone (DBP) and DBP conjugate comprises dimers and oligomers.